C=o Other Than As Ketone Or Aldehyde, Attached Directly Or Indirectly To Phosphorus Patents (Class 514/120)
-
Patent number: 11648226Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).Type: GrantFiled: September 21, 2020Date of Patent: May 16, 2023Assignee: Indiana University Research and Technology CorporationInventors: Mark R. Kelley, Melissa L. Fishel
-
Patent number: 11466029Abstract: The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus.Type: GrantFiled: January 5, 2022Date of Patent: October 11, 2022Assignee: NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD.Inventors: Xiaolin Hao, Jinfu Yang
-
Patent number: 11077150Abstract: The invention includes compositions and methods of administering the compositions to improve the condition of damaged eye tissues. The compositions include cannabinoids such as cannabidiol and one or more of human stem cell products, lutein, and N-acetyl carnosine. The compositions include components that are encapsulated and may include a mixture of separately encapsulated materials. The methods include administering the compositions as drops to an affected eye.Type: GrantFiled: October 7, 2019Date of Patent: August 3, 2021Inventors: Travis Castro, Tricia Scribner, Massoumeh Kharazmi
-
Patent number: 11020438Abstract: The invention provides improved processes for extracting and preparing polar lipids (in particular, desirable phospholipids) from krill and other biological sources. The inventors have discovered processes through which it is possible to extract phospholipids to give high phospholipid content and a reduction of undesired components.Type: GrantFiled: September 25, 2019Date of Patent: June 1, 2021Assignee: Aker BioMarine Antarctic ASInventors: Finn Myhren, Nils Hoem, Håvard Thøgersen
-
Patent number: 10786516Abstract: The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The compositions are administered to patients having migraines having trigeminal or occipital neuralgia by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves.Type: GrantFiled: November 25, 2019Date of Patent: September 29, 2020Inventor: Faro Owiesy
-
Patent number: 10736915Abstract: Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of ?-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B.Type: GrantFiled: February 5, 2018Date of Patent: August 11, 2020Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, NORTHWESTERN UNIVERSITYInventors: Samuel H. Gellman, Shannon S. Stahl, Brendan P. Mowery, Annelise Barron, Michelle Dohm
-
Patent number: 10729142Abstract: The present invention is directed to methods of producing de-oiled sabadilla extract by removing the oil from sabadilla seeds or a sabadilla extract. The invention also relates to methods for controlling pests by application of de-oiled sabadilla extract to pests' or to their environment.Type: GrantFiled: October 18, 2018Date of Patent: August 4, 2020Assignee: McLaughlin Gormley King CompanyInventors: John Thomas Bergman, Darrick David Unger
-
Patent number: 10729143Abstract: The present invention is directed to methods of producing liquid sabadilla extract. The invention also relates to methods for controlling pests by application of liquid sabadilla seed extract to pests' environment or to pests.Type: GrantFiled: October 18, 2018Date of Patent: August 4, 2020Assignee: McLaughlin Gormley King CompanyInventors: John Thomas Bergman, Darrick David Unger
-
Patent number: 10023912Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.Type: GrantFiled: December 4, 2015Date of Patent: July 17, 2018Assignee: EXIQON A/SInventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
-
Patent number: 9963443Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.Type: GrantFiled: June 8, 2015Date of Patent: May 8, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tatsuki Koike, Shuhei Ikeda
-
Patent number: 9925213Abstract: Non-natural oligomers have recently shown promise as functional analogs of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of ?-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B.Type: GrantFiled: May 1, 2015Date of Patent: March 27, 2018Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, NORTHWESTERN UNIVERSITYInventors: Samuel H. Gellman, Shannon S. Stahl, Brendan P. Mowery, Annelise Barron, Michelle Dohm
-
Patent number: 9775850Abstract: The invention is directed to methods and compositions for curing migraine headaches. In particular, compositions are described involving the combination of dexamethasone, lidocaine, and thiamine. The methods of curing a patient of migraines having trigeminal or occipital neuralgia involves administering, by subcutaneous injection during a single treatment session, a combination of dexamethasone, lidocaine and thiamine to several craniofacial nerves.Type: GrantFiled: September 27, 2016Date of Patent: October 3, 2017Inventor: Faro Owiesy
-
Patent number: 9295683Abstract: The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil.Type: GrantFiled: March 11, 2014Date of Patent: March 29, 2016Assignee: AKER BIOMARINE ANTARCTIC ASInventors: Kjetil Berge, Lena Burri
-
Patent number: 9040505Abstract: Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component.Type: GrantFiled: September 22, 2008Date of Patent: May 26, 2015Assignee: Indiana University Research and Technology CorporationInventor: Mark R. Kelley
-
Publication number: 20150110866Abstract: A complex is provided, including a phospholipid and curcumin, wherein some or all of the phospholipid is a marine phospholipid. In addition, a composition is provided including a complex with a phospholipid and curcumin, wherein some or all of the phospholipid in the complex is a marine phospholipid. In addition, a method is provided of preparing a complex or composition including the steps of: a) forming a first solution by dissolving a quantity of curcumin in a solvent; b) forming a further solution by adding slowly to the first solution a suitable quantity of a marine phospholipid; c) processing the further solution to form the complex; and d) separating the complex from the solvent by distillation.Type: ApplicationFiled: December 24, 2014Publication date: April 23, 2015Inventor: Harold Gordon Cave
-
Patent number: 9006144Abstract: Aqueous glyphosate formulations comprising a surfactant derived from metathesized natural oil feedstocks are disclosed. The formulations comprise a glyphosate salt, water, and a surfactant derived from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives. The surfactant is selected from C10 or C12 amine oxides, C10 or C12 quats, C10, C12, or C16 amidoamines, C10 or C12 amidoamine oxides, C10 imidazoline quats, C10 or C12 amidoamine quats, C10, C12, or C16 betaines, C16 amidoamine betaines, C18 diamidoamines, C18 diamidoamine oxides, C18 diamidoamine diquats, C18 diamidoamine oxide quats, C18 diamidoamine oxide betaines, Cis diamidoamine monobetaines, C18 diamidoamine monobetaine quats, C18 ester amidoamine quats, and amidoamines and their oxidized or quaternized derivatives made from self- or cross-metathesized palm or soybean oil.Type: GrantFiled: October 25, 2011Date of Patent: April 14, 2015Assignee: Stepan CompanyInventors: Dave R. Allen, Randal J. Bernhardt, Andrew D. Malec, Patrick Shane Wolfe
-
Patent number: 9006219Abstract: The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.Type: GrantFiled: March 12, 2009Date of Patent: April 14, 2015Assignee: Nektar TherapeuticsInventors: Timothy A. Riley, Lin Cheng
-
Publication number: 20150087510Abstract: Fungicidal mixtures, comprising as active components 1) at least one 1-methylpyrazol-4-ylcarboxanilide of the formula I where R1?C1-C4-alkyl or C1-C4-haloalkyl, R2=hydrogen or halogen, X=hydrogen or halogen, Q=direct bond, a cyclopropylene or an anellated bicyclo[2.2.Type: ApplicationFiled: September 29, 2014Publication date: March 26, 2015Inventors: Markus GEWEHR, Ulf GROEGER, Egon HADEN, Michael VONEND
-
Publication number: 20150087621Abstract: Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.Type: ApplicationFiled: March 26, 2013Publication date: March 26, 2015Inventors: Federica Pericle, Jeremy A. Ross
-
Patent number: 8962600Abstract: Apocynin derivative compounds, active pharmaceutical ingredients, dosage forms, and methods of use thereof as neuroprotectants in the brain of mammals.Type: GrantFiled: April 15, 2010Date of Patent: February 24, 2015Assignee: The Medical College of Wisconsin, Inc.Inventors: Balaraman Kalyanaraman, Joy Joseph, Anumantha Kanthasamy
-
Publication number: 20150030541Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.Type: ApplicationFiled: October 14, 2014Publication date: January 29, 2015Inventor: Thomas E. Rogers
-
Publication number: 20140378529Abstract: Methods for treating a subject determined to have a cancer comprising a heterozygous inactivation of a housekeeping gene (or a homozygous deletion of a functionally redundant housekeeping gene) by treating the subject with an inhibitor of the gene. For example, a subject having a cancer with an ENO gene deletion can be treated with a glycolysis inhibitor, such as an enolase inhibitor. In some aspects, a subject having a cancer with an ARS gene deletion can be treated with an ARS inhibitor.Type: ApplicationFiled: December 14, 2012Publication date: December 25, 2014Applicants: DANA-FARBER CANCER INSTITUTE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Florian L. Muller, Eliot Fletcher-Sananikone, Simona Colla, Elisa Aquilanti, Ronald DePinho
-
Publication number: 20140371177Abstract: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventors: Charles C-Y Shih, Toshio Kitamura, Qian Shi, Toshiyuki Kawashima, Hui-Kang Wang
-
Patent number: 8883765Abstract: Artemisinin-derived monomers and artemisinin dimers are shown to exhibit in-vitro anti-cytomegalovirus (CMV) activity. Artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts with no cytotoxicity at concentrations required for complete CMV inhibition. Artemisinin dimers were found to be potent and non-cytotoxic inhibitors of CMV replication, which indicates their use as therapeutic agents for the treatment of CMV infection in humans.Type: GrantFiled: December 8, 2010Date of Patent: November 11, 2014Assignee: The John Hopkins UniversityInventors: Ravit Arav-Boger, Gary Posner
-
Publication number: 20140329775Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.Type: ApplicationFiled: February 17, 2014Publication date: November 6, 2014Inventor: Scott G. Petersen
-
Publication number: 20140315834Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.Type: ApplicationFiled: September 23, 2013Publication date: October 23, 2014Applicant: Medicon Pharmaceuticals, Inc.Inventor: Basil RIGAS
-
Patent number: 8865685Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.Type: GrantFiled: June 13, 2012Date of Patent: October 21, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventor: Annabelle Gallois-Bernos
-
Publication number: 20140301979Abstract: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.Type: ApplicationFiled: June 25, 2014Publication date: October 9, 2014Applicant: SIGA TECHNOLOGIES, INC.,Inventors: Sean M. AMBERG, Dongcheng DAI, Tove C. BOLKEN, Dennis E. HRUBY
-
Patent number: 8853195Abstract: Disclosed is a composition for reducing the exudation of the serum proteins. More specifically the composition of the present invention relates to a composition capable of improving conditions such as atopic dermatitis, atopic eczema, skin pruritus, atopic nasitis, atopic erythema or erythroderma, contact dermatitis, asthma, chronic obstructive pulmonary disease, etc. by reducing the exudation of the serum proteins in skin and mucosa.Type: GrantFiled: February 23, 2006Date of Patent: October 7, 2014Assignee: KT & G CorporationInventor: Seong-hyun Choi
-
Patent number: 8846567Abstract: The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I) in which R1 and A have the meanings given in the description and, secondly, at least one further known active compound from the class of the organophosphates or carbamates, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids.Type: GrantFiled: March 25, 2009Date of Patent: September 30, 2014Assignee: Bayer CropScience AGInventors: Heike Hungenberg, Peter Jeschke, Robert Velten, Wolfgang Thielert
-
Publication number: 20140288017Abstract: The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.Type: ApplicationFiled: October 12, 2012Publication date: September 25, 2014Inventors: William L. Jorgensen, Karen S. Anderson
-
Publication number: 20140274967Abstract: This invention relates generally to polyisoprenyl phosphonate derivatives pharmaceutical compositions comprising polyisoprenyl phosphonate derivatives, and uses thereof.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: COYOTE PHARMACEUTICALS, INC.Inventors: William Boyle, Naoki Nakayama
-
Publication number: 20140274968Abstract: The invention relates to omega-3 phospholipid supplements for use in adolescents, and in particular to use omega-3 phospholipid supplements to improve or support brain maturity age. In preferred embodiments, the omega-3 phospholipid is krill oil.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventors: Kjetil Berge, Lena Burri
-
Patent number: 8796243Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.Type: GrantFiled: January 2, 2013Date of Patent: August 5, 2014Assignee: National Jewish HealthInventor: Dennis R. Voelker
-
Patent number: 8778914Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.Type: GrantFiled: August 24, 2010Date of Patent: July 15, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Katrin Hochdoerffer
-
Patent number: 8759315Abstract: A ribose-related compound is added to whole blood or packed red cells which have suboptimal function as measured by decreased levels of 2,3-DPG in order to rejuvenate the red blood cells to normal function as seen by raised levels of 2,3-DPG. Two representative ribose-related compounds are D-ribose and inosine.Type: GrantFiled: January 5, 2007Date of Patent: June 24, 2014Assignee: Viacell, LLCInventors: John A St. Cyr, Daniel G Ericson, Clarence A Johnson
-
Publication number: 20140170112Abstract: In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.Type: ApplicationFiled: March 8, 2012Publication date: June 19, 2014Applicant: VICUS THERAPEUTICS, LLCInventors: John Maki, Newell Bascomb, Timothy J. Turner, Fredric Young
-
Publication number: 20140141972Abstract: This invention pertains to methods for protecting a propagule or a plant grown therefrom from invertebrate pests comprising contacting the propagule or the locus of the propagule with a biologically effective amount of a compound of Formula I, its N-oxide or an agriculturally suitable salt thereof wherein A and B and R1 through R8 are as defined in the disclosure. This invention also relates to propagules treated with a compound of Formula I and compositions comprising a Formula I compound for coating propagules.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: E I DU PONT NEMOURS AND COMPANYInventors: RICHARD ALAN BERGER, Isaac Billy Annan, George Philip Lahm, John Lindsey Flexner, Thomas Paul Selby, Thomas Martin Stevenson
-
Publication number: 20140140973Abstract: This invention pertains to a method for controlling lepidopteran, homopteran, hemipteran, thysanopteran and coleopteran insect pests comprising contacting the insects or their environment with an arthropodicidally effective amount of a compound of Formula I, its N-oxide or an agriculturally suitable salt thereof wherein A and B and R1 through R8 are as defined in the disclosure. This invention further relates to a bezoxazinone compound of Formula 10 wherein R4 through R8 are as defined in the disclosure, useful for preparation of a compound of Formula I.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: GEORGE PHILIP LAHM, Stephen Frederick McCann, Kanu Maganbhai Patel, Thomas Paul Selby, Thomas Martin Stevenson
-
Patent number: 8722649Abstract: Described herein is the synthesis and pharmacology of a series of ?-substituted methylene phosphonate analogs, in which the ?-CH2 moiety is replaced with CHCl or CHBr.Type: GrantFiled: June 13, 2008Date of Patent: May 13, 2014Assignees: University of Utah Research Foundation, University of Tennessee Research FoundationInventors: Glenn Prestwich, Gabor Tigyi, Guowei Jiang, Guanghui Yang, Joanna Gajewiak, Honglu Zhang, Xiaoyu Xu
-
Patent number: 8710033Abstract: The objective is to find compounds which have an activity to improve the success rate of pregnancy and implantation in blastocyst transfer in mammals, to provide a method of producing and using the compounds, and to provide a pregnancy-promoting agent. Disclosed is a pregnancy-promoting agent containing one or more lysophosphatidic acids selected from the group consisting of LPA-C16:0, LPA-C16:1, LPA-C18:0, LPA-C18:1 and LPA-C18:2.Type: GrantFiled: August 25, 2010Date of Patent: April 29, 2014Assignees: JCR Pharmaceuticals Co., Ltd.Inventors: Masahide Shiotani, Sakae Goto, Mitsuo Shimizu
-
Patent number: 8709454Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.Type: GrantFiled: January 12, 2010Date of Patent: April 29, 2014Assignee: L'OrealInventors: David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
-
Publication number: 20140088045Abstract: The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and/or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and/or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.Type: ApplicationFiled: August 28, 2013Publication date: March 27, 2014Inventors: Basil Rigas, Jason B. Rigas
-
Publication number: 20140088047Abstract: The present invention relates to the use of long chain polyunsaturated fatty acids to treat diseases associated with red blood cells and cell membranes, and in particular to the use of derivatives of long chain fatty acids to treat sickle cell disease.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: AKER BIOASSIST ASInventors: Nils Hoem, Elizabeth B. Vadas
-
Publication number: 20140088044Abstract: The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and/or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence.Type: ApplicationFiled: August 28, 2013Publication date: March 27, 2014Inventors: Basil Rigas, Jason B. Rigas
-
Patent number: 8680080Abstract: A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.Type: GrantFiled: October 24, 2011Date of Patent: March 25, 2014Assignee: Neptune Technologies & Bioressources, Inc.Inventor: Fotini Sampalis
-
Publication number: 20140080791Abstract: The invention relates to omega-3 phospholipid supplements for females, and in particular to omega-3 phospholipid supplements with increased bioavailability as evidenced by increased EPA and DHA in plasma phospholipids and an increase in omega-3 index as compared to males. In preferred embodiments, the omega-3 phospholipid is krill oil.Type: ApplicationFiled: September 17, 2013Publication date: March 20, 2014Inventors: Kjetil Berge, Nils Hoem
-
Publication number: 20140044690Abstract: A method of treating or preventing a neurodegenerative disease includes administering an effective amount of a compound to a subject in need thereof. The compound includes a high-energy compound, such as adenosine triphosphate (ATP), guanosine triphosphate (GTP), phosphocreatine (PCr), acetyl coenzyme A (ACoA), phosphoenol pyruvate (PEP), or a combination thereof.Type: ApplicationFiled: August 7, 2013Publication date: February 13, 2014Applicants: U.S. Department of Veterans AffairsInventors: Ming CHEN, Darrell R. Sawmiller, Huey T. Nguyen
-
Publication number: 20130338113Abstract: The subject invention provides materials and methods for treating various health conditions, including the prevention and/or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).Type: ApplicationFiled: April 4, 2013Publication date: December 19, 2013Applicant: OBIO PHARMACEUTICAL (H.K.) LIMITEDInventors: HAO YI LIANG, FRANCIS CHI, QINGFU XU, BILL PIU CHAN
-
Patent number: 8586567Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.Type: GrantFiled: October 29, 2010Date of Patent: November 19, 2013Assignee: Acasti Pharma, Inc.Inventors: Fotini Sampalis, Henri Harland